

To: (10)(2e) (10)(2e) @novacyt.com]; (10)(2e) (10)(2e) @novacyt.com]
Cc: (10)(2e) (10)(2e) @rivm.nl]
From: (10)(2e) (10)(2e)
Sent: Tue 5/12/2020 1:40:37 PM
Subject: Rebuttal request PrimerDesign
Received: Tue 5/12/2020 1:40:38 PM

Dear (10)(2e)

I have forwarded your request to the people that should be able to address your question, but they probably haven't found the time yet to respond to you. As you are probably aware, we are a national public health institute and currently in the midst of a time-consuming public health crisis. We have performed this comparison as a courtesy to the global diagnostics community. We did not have the time or resources to spare to provide an extensive clinical validation, our work thus provides an indication of the acceptability of the kits and they all "passed the test", yours included. The results might not exactly match the findings within your own laboratory, but we are an experienced molecular diagnostic lab with a good reputation and I am confident that our findings fall within the boundaries of what might be expected to be obtained by any comparable lab in the field.

I will forward your request again, but I cannot guarantee you'll get a response in the near future. It is also not entirely clear to me how you envision your "offering a rebuttal letter"; what is it exactly that you expect us to do with this letter? Furthermore, I'd like to point out that a manuscript concerning these data has recently been accepted by the Journal of Clinical Virology (<https://doi.org/10.1016/j.jcv.2020.104412>). Please take a look at the manuscript, as you might find that some of your concerns have been addressed.

Kind regards,

(10)(2e)

(10)(2e) (10)(2e) (10)(2e) (10)(2e)

(10)(2e)

Department Immune Mechanisms (IMM)
 Centre for Immunology of Infectious diseases and Vaccines (IIV)
 National Institute for Public Health and the Environment (RIVM)

Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | (10)(2e)
 Postbus 1 | 3720 BA Bilthoven

T (10)(2e)
 (10)(2e) @rivm.nl

(10)(2e)

From: (10)(2e) <(10)(2e)@novacyt.com>
Sent: dinsdag 12 mei 2020 15:07
To: (10)(2e) (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@novacyt.com>
Cc: (10)(2e) <(10)(2e)@rivm.nl>
Subject: RE: Report COVID-19 RT-PCR kits RIVM

Dear (10)(2e)

I haven't received any further correspondence from you regarding a way of offering an official rebuttal to your paper. I ask kindly that you please extend this courtesy to me?

Best regards

(10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl>
Sent: 18 April 2020 12:36
To: (10)(2e) <(10)(2e)@novacyt.com>; (10)(2e) <(10)(2e)@novacyt.com>
Cc: (10)(2e) <(10)(2e)@rivm.nl>
Subject: RE: Report COVID-19 RT-PCR kits RIVM

Dear (10)(2e),

(10)(2g)

(10)(2g)

As for the data, this is what we found. Notably, we do not provide a negative assessment of your kit, nor do we discourage its use.

Have a nice weekend.

Best,

(10)(2e)

(10)(2e) (10)(2e) (10)(2e)

(10)(2e)

Department Immune Mechanisms (IMM)
Centre for Immunology of Infectious diseases and Vaccines (IIV)
National Institute for Public Health and the Environment (RIVM)

Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | (10)(2e)
Postbus 1 | 3720 BA Bilthoven

T (10)(2e)
(10)(2e)@rivm.nl

(10)(2e)

From: (10)(2e) <(10)(2e)@novacyt.com>
Sent: zaterdag 18 april 2020 11:55
To: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@novacyt.com>
Cc: (10)(2e) <(10)(2e)@rivm.nl>
Subject: Re: Report COVID-19 RT-PCR kits RIVM

Hi (10)(2e)

Thank you for sending the report over.

I will distribute to my colleagues next week, but there are a few queries I would have with it.

(10)(2g)

(10)(2g)

(10)(2g)

(10)(2g)

(10)(2g)

Thank you

(10)(2e)

Get [Outlook for iOS](#)

From: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>
Sent: Saturday, April 18, 2020 10:33:20 AM
To: (10)(2e) <(10)(2e)@novacyt.com>; (10)(2e) <(10)(2e)@novacyt.com>
Cc: (10)(2e) <(10)(2e)@rivm.nl>
Subject: Report COVID-19 RT-PCR kits RIVM

Dear (10)(2e) and (10)(2e)

Please find attached our report concerning the comparison of 7 COVID-19 RT-PCR kits. We have sent this report to WHO/ECDC and will submit it for publication in a peer-reviewed journal shortly.

Kind regards,

(10)(2e)

(10)(2e) (10)(2e) (10)(2e)
(10)(2e)

Department Immune Mechanisms (IMM)
Centre for Immunology of Infectious diseases and Vaccines (IIV)
National Institute for Public Health and the Environment (RIVM)

Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | (10)(2e)
Postbus 1 | 3720 BA Bilthoven

T (10)(2e)
(10)(2e)@rivm.nl

(10)(2e)

-----Original Message-----

From: (10)(2e) <(10)(2e)@novacyt.com>
Sent: vrijdag 3 april 2020 15:53
To: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>; Gaylynn Almeida <(10)(2e)@novacyt.com>; (10)(2e) <(10)(2e)@novacyt.com>
Subject: RE: Sales Order Acknowledgement 0000105411 - FOC comparison study by Dutch authorities.

Hi (10)(2e)

These 2 kits will be sent to you today. Customer care team will send you the tracking details.

Many thanks,

(10)(2e)

-----Original Message-----

From: (10)(2e) (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>
Sent: 02 April 2020 18:40
To: (10)(2e) (10)(2e) <(10)(2e)@novacyt.com>; (10)(2e) <(10)(2e)@novacyt.com>; (10)(2e) (10)(2e) <(10)(2e)@novacyt.com>
Subject: RE: Sales Order Acknowledgement 0000105411 - FOC comparison study by Dutch authorities.

Dear (10)(2e),

Could you please provide an estimate of the delivery date of the kits so that we can plan our experiments?

Thanks!

Best,

(10)(2e)

(10)(2e) (10)(2e) (10)(2e) (10)(2e)
(10)(2e)

Department Immune Mechanisms (IMM)
Centre for Immunology of Infectious diseases and Vaccines (IIV) National Institute for Public Health and the Environment (RIVM)

Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | (10)(2e) | 3720 BA Bilthoven

T (10)(2e)
(10)(2e)@rivm.nl

(10)(2e)

-----Original Message-----

From: (10)(2e) <(10)(2e)@novacyt.com>
Sent: maandag 30 maart 2020 13:39
To: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) <(10)(2e)@novacyt.com>
Subject: Sales Order Acknowledgement 0000105411 - FOC comparison study by Dutch authorities.

Sales Order 0000105411 from National Institute for Public Health and the Environment (RI

Dear (10)(2e) (10)(2e) (10)(2e),

Please find attached a copy of your order (reference FOC - comparison study by Dutc), our sales order (reference 0000105411).

If you have any questions regarding the sales order please contact us using the details below.

Kind regards

(10)(2e)
Email: (10)(2e)@novacyt.com

Primerdesign Ltd

Part of the Novacyt Group

<https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.primerdesign.co.uk%2F&data=02%7C01%7Craj.bhagwati%40novacyt.com%7C946b8511053248590b3b08d7d72ce3de%7C7f86b855a6074882a2cf7ae773bd7869%7C0%7C0%7C637214460110169294&sd=ym00BYwBug7rASKsg1XLnxgrCRc1pLP985Kijxv2LM8%3D∓reserved=0>
 Facebook | Twitter | LinkedIn

Office: (10)(2e)

Direct Line: (10)(2e)

York House, School Lane, Chandlers Ford, United Kingdom, SO53 4DG

Disclaimer. The information contained in this communication from (10)(2e)@primerdesign.co.uk is confidential and may be legally privileged. It is intended solely for use by the authorised receiver. If you are not the authorised receiver you are hereby notified that any disclosure, copying, distribution or taking action in reliance of the contents of this information is strictly prohibited and may be unlawful.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

<https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.rivm.nl%2F&data=02%7C01%7Craj.bhagwati%40novacyt.com%7C946b8511053248590b3b08d7d72ce3de%7C7f86b855a6074882a2cf7ae773bd7869%7C0%7C0%7C637214460110169294&sd=ym00BYwBug7rASKsg1XLnxgrCRc1pLP985Kijxv2LM8%3D∓reserved=0><<https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.rivm.nl%2F&data=02%7C01%7Craj.bhagwati%40novacyt.com%7C946b8511053248590b3b08d7d72ce3de%7C7f86b855a6074882a2cf7ae773bd7869%7C0%7C0%7C637214460110169294&sd=ym00BYwBug7rASKsg1XLnxgrCRc1pLP985Kijxv2LM8%3D∓reserved=0>> De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

<https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.rivm.nl%2F&data=02%7C01%7Craj.bhagwati%40novacyt.com%7C946b8511053248590b3b08d7d72ce3de%7C7f86b855a6074882a2cf7ae773bd7869%7C0%7C0%7C637214460110169294&sd=LtQXTFBn2bsFD5QN9VeGK%2Bp2JMEvILh3Gg3ijzGA5m8%3D∓reserved=0><<https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.rivm.nl%2F&data=02%7C01%7Craj.bhagwati%40novacyt.com%7C946b8511053248590b3b08d7d72ce3de%7C7f86b855a6074882a2cf7ae773bd7869%7C0%7C0%7C637214460110169294&sd=LtQXTFBn2bsFD5QN9VeGK%2Bp2JMEvILh3Gg3ijzGA5m8%3D∓reserved=0>> Committed to health and sustainability

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability